Loading…
REGENXBIO Inc. is projected to rise to $23.45 by 2027, a +68% move from its current price of $13.95. RGNX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $13.22 | $13.99 | $14.80 | +0.27% |
| Jul 14 | $12.94 | $14.02 | $15.20 | +0.54% |
| Jul 15 | $12.75 | $14.06 | $15.51 | +0.80% |
| Jul 16 | $12.59 | $14.10 | $15.79 | +1.07% |
| Jul 17 | $12.45 | $14.14 | $16.05 | +1.34% |
| Jul 18 | $12.34 | $14.18 | $16.29 | +1.62% |
| Jul 19 | $12.23 | $14.21 | $16.51 | +1.89% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.23 | $14.21 | $16.51 | +1.89% |
| Week 2 | $11.71 | $14.48 | $17.90 | +3.81% |
| Week 3 | $11.38 | $14.75 | $19.13 | +5.77% |
| Week 4 | $11.14 | $15.03 | $20.29 | +7.76% |
| Week 5 | $10.95 | $15.32 | $21.42 | +9.80% |
| Week 6 | $10.81 | $15.61 | $22.54 | +11.87% |
| Week 7 | $10.69 | $15.90 | $23.65 | +13.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
REGENXBIO Inc. is a clinical-stage biotechnology company that provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its products are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
REGENXBIO pipelines include ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; RGX-202 for the treatment of Duchenne muscular dystrophy; RGX-121 for the treatment of mucopolysaccharidosis type II; and RGX-111 for the treatment of mucopolysaccharidosis type I. The company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd.
to develop RGX-121 and RGX-111 outside the United States. REGENXBIO was incorporated in 2008 and is headquartered in Rockville, Maryland.
REGENXBIO Inc. (RGNX) is currently trading at $14.83 per share, with a market capitalization of $766.68M and a rank of 2713. The current price and market position place it among smaller-cap healthcare stocks with a biotechnology focus.
The 30-day forecast shows a path that begins neutral in 2026 and shifts to bullish thereafter, with a long-run upside reflected in the year-by-year forecast. The maximum forecast values through 2050 imply substantial potential upside from today’s level.
A major floor 83.3% below — a decisive break under it would weaken the trend.
The nearest floor, 56.4% below — buyers have tended to step in here.
The nearest ceiling, 12.2% above — a clean break opens room to run.
A major ceiling 53.9% above — clearing it would confirm fresh momentum.
Key RGNX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RGNX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.94 | Sell | $14.45 | Sell |
| MA 10 | $13.53 | Buy | $13.46 | Buy |
| MA 20 | $10.86 | Buy | $11.72 | Buy |
| MA 50 | $8.90 | Buy | $9.87 | Buy |
| MA 100 | $8.81 | Buy | $9.58 | Buy |
| MA 200 | $10.56 | Buy | $9.79 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.72 | Neutral |
| Stoch RSI (14) | 16.09 | Buy |
| CCI (20) | 75.96 | Neutral |
| Williams %R (14) | -25.84 | Info |
| MACD (12,26,9) | 0.44 | Buy |
| ROC (12) | 40.20 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 74.16 | Neutral |
| TRIX (15) | 2.66 | Buy |
| Awesome (5,34) | 5.84 | Buy |
| Ultimate (7,14,28) | 73.20 | Sell |
| Momentum (10) | 3.71 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 15.70 | Sell |
| ADX (14) | 44.57 | Buy |
| ATR (14) | 0.58 | Info |
The 30-day technical picture is bullish on current momentum even as the 14-day RSI sits at 90. The 30-day range is $10.13 to $21.72, signaling substantial near-term volatility. The stock trades relative to its moving averages, with the SMA50 at $8.40 and the SMA200 at $10.44, suggesting a potential to move higher.
The current price of $14.83 sits near resistance at $14.83 and above support at $6.08, indicating room for a bullish breakout if momentum persists. Annualized volatility is high at 100%, underscoring the potential for sharp price swings in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.65 | $13.95 | $27.46 | 0% | Neutral | |
| $17.01 | $23.45 | $34.94 | +68% | Bullish | |
| $19.97 | $29.24 | $46.44 | +110% | Bullish | |
| $22.17 | $34.21 | $57.03 | +145% | Bullish | |
| $20.53 | $33.21 | $57.63 | +138% | Bullish | |
| $22.73 | $38.43 | $69.03 | +175% | Bullish | |
| $30.00 | $52.91 | $98.00 | +279% | Bullish | |
| $40.87 | $75.04 | $142.87 | +438% | Bullish | |
| $44.38 | $84.77 | $165.47 | +508% | Bullish | |
| $41.89 | $83.18 | $166.15 | +496% | Bullish | |
| $72.71 | $161.57 | $354.68 | +10.6x | Bullish | |
| $141.75 | $315.00 | $724.49 | +21.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.65 | $13.95 | $17.61 | +0.00% |
| August 2026 | $13.53 | $16.38 | $20.66 | +17.44% |
| September 2026 | $14.49 | $17.80 | $22.92 | +8.63% |
| October 2026 | $14.42 | $17.93 | $23.50 | +0.75% |
| November 2026 | $14.98 | $18.83 | $25.03 | +5.00% |
| December 2026 | $16.07 | $20.38 | $27.46 | +8.27% |
Click any year to see its month-by-month RGNX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RGNX is projected to trade between $5.65 and $27.46, averaging $13.95 — a potential gain of 0% from today's $13.95. Price action looks broadly range-bound.
REGENXBIO Inc.'s 2027 outlook centres on $23.45, within a $17.01 to $34.94 range. That is up +68% on the projected 2026 average. That marks a +68% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, RGNX could reach as high as $46.44, with a base case around $29.24 and support toward $19.97 — roughly +110% from $13.95. Momentum favours further upside here.
Expect RGNX to range from $22.17 to $57.03 through 2029. The $34.21 average target implies a +145% move from current prices. That is up +17% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The RGNX price prediction for 2030 points to an average of $33.21 (low $20.53, high $57.63) — a potential gain of +138% on today's $13.95. Momentum favours further upside here.
In 2031, RGNX is projected to trade between $22.73 and $69.03, averaging $38.43 — a potential gain of +175% from today's $13.95. That is up +16% on the projected 2030 average. Buyers look set to stay in control over this stretch.
REGENXBIO Inc.'s 2032 outlook centres on $52.91, within a $30.00 to $98.00 range. That is up +38% on the projected 2031 average. That marks a +279% change versus current levels. Momentum favours further upside here.
By 2033, RGNX could reach as high as $142.87, with a base case around $75.04 and support toward $40.87 — roughly +438% from $13.95. Buyers look set to stay in control over this stretch.
Expect RGNX to range from $44.38 to $165.47 through 2034. The $84.77 average target implies a +508% move from current prices. That is up +13% on the projected 2033 average. Momentum favours further upside here.
The RGNX price prediction for 2035 points to an average of $83.18 (low $41.89, high $166.15) — a potential gain of +496% on today's $13.95. Buyers look set to stay in control over this stretch.
In 2040, RGNX is projected to trade between $72.71 and $354.68, averaging $161.57 — a potential gain of +10.6x from today's $13.95. That is up +94% on the projected 2035 average. Momentum favours further upside here.
REGENXBIO Inc.'s 2050 outlook centres on $315.00, within a $141.75 to $724.49 range. That is up +95% on the projected 2040 average. That marks a +21.6x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in RGNX today (≈ 71.684588 RGNX) could be worth
$22,580.35
+$21,580.35 (+2158%) by 2050 · US Dollar
Based on the average projected RGNX price of $315 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RGNXwould be worth at today's price.
$1,000 invested in RGNX on Jul 10, 2025 (≈ 110.375271 RGNX) would be worth
$1,539.74
+$539.74 (+54.0%) today · 1.54× · US Dollar
Based on a RGNX entry price of $9.06 vs. today's $13.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.28 | $1,050.45 | +5.0% |
| 1 month ago | $6.13 | $2,275.69 | +127.6% |
| 3 months ago | $8.8 | $1,585.23 | +58.5% |
| 6 months ago | $15.08 | $925.07 | -7.5% |
| 1 year ago | $9.06 | $1,539.74 | +54.0% |
| All time (5.0y) ago | $36.51 | $382.09 | -61.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RGNX forecast.
Our base-case forecast reaches $28.00 around 2028.
Implied market cap at $28.00: $1.45B
The multi-year forecast shows a clear upward trajectory in average prices and sizable ROI potential, with 2026 expected to average $14.83 and 2027 through 2050 showing progressively higher averages and bullish sentiment. Key milestones include 2030 with an average of $32.35 and ROI 118.2, 2040 with an average of $160.69 and ROI 983.6, and 2050 with an average of $303.65 and ROI 1947.5. The forecast also presents higher maximums over time, up to $56.18 in 2030 and as high as $698.39 by 2050, all while sentiment remains bullish beyond 2026.
These figures are estimates and not guarantees. The long-run outlook reflects potential appreciation consistent with the projected averages and max values, but actual results will depend on market conditions and other factors not stated here.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $32.35 with a max of $56.18 and a min of $19.99; the forecast indicates an ROI of 118.2 and bullish sentiment.
From 2027 onward the forecast is bullish with rising averages (e.g., 2027 avg $23.56, 2028 avg $29.54, 2029 avg $34.24) and strong ROI values, though 2026 is neutral. These are estimates, not guarantees.
Yes. The forecast shows higher price tops such as 2032 max $102.53, 2033 max $142.36, 2034 max $163.96, and 2040 max $352.83, with 2050 max $698.39.
Current price is $14.83 and market cap is $766.68M.
The 30-day range is $10.13 to $21.72, RSI14 is 90, SMA50 is $8.40, SMA200 is $10.44, with support at $6.08 and resistance at $14.83; sentiment is BULLISH and annualized volatility is 100%.
REGENXBIO Inc. Community Discussion
0Share your REGENXBIO Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.